Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1

Inclusion Criteria: * patients who were clinically diagnosed with narcolepsy type 1 * aged10-60 years, male or female. * A lumbar puncture was performed to evaluate the CSF orexin-A level. * HLA typing was performed. * Patients who had previously failed (no response or no maintenance) guideline- specified first-line therapy for narcolepsy and had previously received at least one guideline-specified second-line treatment for narcolepsy type 1and failed (no response or no maintenance). Or patients who refused to drug treatment. * Subjects with no significant laboratory abnormalities during screening. * Patients and their legal guardians must comprehensively understand and be able to adhere to the study protocol requirements and willingly sign the informed consent form. Exclusion Criteria: * Patients allergic to ofatumumab, or had failed to respond to previous treatment with ofatumumab. * Patients were excluded if they had a previous immune disease, or patients diagnosed with various secondary and hereditary auto-immune disorders, contraindications to lumbar puncture, conditions or medication with known substantial impact on the immune system, with impact on the result of lumbar puncture. * Patients with uncontrollable primary diseases of important organs, such as liver failure, heart failure, renal failure and other diseases. * Patients who are positive for HIV antibodies or syphilis antibodies. * Patients accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus, etc.